New method separates cancer cells from normal cellsJune 16, 2009The vast majority of cancer deaths are due to metastasis, the spread of cancer cells from its primary site to other parts of the body. These metastatic cells tend to move more than their non-metastatic variants but this movement is poorly understood. Scientists are studying cancer cells intently with the hope they can learn to control the movements of the dangerous cells. Northwestern University researchers now have demonstrated a novel and simple method that can direct and separate cancer cells from normal cells. Based on this method, they have proposed that cancer cells possibly could be sequestered permanently in a sort of "cancer trap" made of implantable and biodegradable materials. The demonstrated device, which takes advantage of a physical principle called ratcheting, is a very tiny system of channels for cell locomotion. Each channel is less than a tenth of a millimeter wide. The asymmetric obstacles inside these channels direct cell movement along a preferred direction. Details are published online by the journal Nature Physics. "We have demonstrated a principle that offers an unconventional way to fight metastasis, a very different approach from other methods, such as chemotherapy," said Bartosz Grzybowski, the paper's senior author. "These are fundamental studies so the method needs to be optimized, but the idea has promise for a new approach to cancer therapy." Grzybowski is associate professor of chemical and biological engineering in the McCormick School of Engineering and Applied Science and associate professor of chemistry in the Weinberg College of Arts and Sciences. The researchers first discovered they could design channels of different geometries -- some a series of connected triangles -- through which cells can move in a single direction. (Live mammalian melanoma, breast cancer and normal cells were studied.) To create the channels, the researchers patterned cell-adhesive and cell-repellant chemical compounds onto a substrate. The cells stayed out of the repellant areas and localized onto the "ratchet" channels, which then directed the cells' movements. Grzybowski and his colleagues took this knowledge one critical step farther: they designed channels that successfully moved the cells of two types -- notably, cancerous and non-cancerous -- in opposite directions and thus partly sorted them out. To sort the cells, they took advantage of the cells' different shapes and mobility characteristics. Migrating cancer cells tend to be more round and broad while normal, epithelial cells are long and thin with long protrusions on the ends. The researchers designed a channel with "spikes" coming out at 45-degree angles from the walls, alternating on opposite sides of the channel. This pattern funnels cancer cells in one direction while at the same time directing the normal cells in the opposite direction, as those cells "grab" the spikes and pull themselves through. The researchers showed that a device with a number of these channels leading to a central reservoir, like spokes on a wheel, worked just as well separating cancer and non-cancerous cells. A stack of these radially arranged ratchet channels could be used to create a "cancer trap." "When implanted next to a tumor the particles would guide cancer cells, but not normal cells, inward to the reservoir, where they would be trapped," said Grzybowski. "The particles could also be part of the sutures used during surgical procedures." Northwestern University |
|||||||||||||||||||||
| Related Cancer Cells Current Events and Cancer Cells News Articles Approved lymphoma drug shows promise in early tests against bone cancer A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Taking aim at mysterious DNA structures in the battle against cancer Designers of anti-cancer drugs are aiming their arrows at mysterious chunks of the genetic material DNA that may play a key role in preventing the growth and spread of cancer cells, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine. Experimental agent reduces breast cancer metastasis to bone Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer. Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone. Study reveals a 'missing link' in immune response to disease The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery. Discovery offers potential new pancreatic cancer treatment Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein. Early-stage, HER2-positive breast cancer patients at increased risk of recurrence Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. A Potential Anti-cancer Agent Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. More Cancer Cells Current Events and Cancer Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||